Hansoh Pharmaceutical Group Tumor Drug Gets Clinical Trials Approval From Chinese Regulator

MT Newswires Live2024-12-18

Hansoh Pharmaceutical Group Company (HKG:3692) said that China's National Medical Products Administration (NMPA) gave clinical trial approval for the HS-20110 injection, a new antibody-drug conjugate.

Independently developed by the Group, the drug treats advanced solid tumors, according to a Tuesday filing with the Hong Kong Stock Exchange.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment